Home / Products / Others / 1201902-80-8
MLN9708,MLN-9708,MLN 9708/


Cat.No.ABP000733 Chemical NameMLN9708,MLN-9708,MLN 9708/ MDL: MFCD18251437 MolFormulaC20H23BCl2N2O9 MolWeight517.124 Purity >99%

Chemical Name : MLN9708,MLN-9708,MLN 9708/

CAS : 1201902-80-8

Synonyms: MLN9708

Storage:at -20℃ 2 years


MLN9708(1201902-80-8) is an orally bioavailable second generation proteasome inhibitor with potential antineoplastic activity. MLN9708(1201902-80-8) rapidly hydrolyzes to MLN2238, the biologically active form. It has a shorter proteasome dissociation half-life and improved pharmacokinetics, pharmacodynamics, and antitumor activity compared with bortezomib. It has a larger blood volume distribution at steady state, and analysis of 20S proteasome inhibition and markers of the unfolded protein response confirmed that MLN9708(1201902-80-8) has greater pharmacodynamic effects in tissues than bortezomib. MLN9708(1201902-80-8)showed activity in both solid tumor and hematologic preclinical xenograft models, and we found a correlation between greater pharmacodynamic responses and improved antitumor activity


[1] http://www.cancer.gov/drugdictionary/?CdrID=635527

[2] http://ash.confex.com/ash/2010/webprogram/Paper31616.html